Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Incyte Corp.

Enrolment target

Start

11 Sep 2023

Proportion of participants achieving IGA-CHE-TS at Week 16.

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.